137 related articles for article (PubMed ID: 1716558)
1. Effects of scopolamine on visual evoked potentials in aging and dementia.
Ray PG; Meador KJ; Loring DW; Murro AM; Buccafusco JJ; Yang XH; Zamrini EY; Thompson WO; Thompson EE
Electroencephalogr Clin Neurophysiol; 1991; 80(5):347-51. PubMed ID: 1716558
[TBL] [Abstract][Full Text] [Related]
2. Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease.
Bajalan AA; Wright CE; van der Vliet VJ
J Neurol Neurosurg Psychiatry; 1986 Feb; 49(2):175-82. PubMed ID: 3950635
[TBL] [Abstract][Full Text] [Related]
3. Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory.
Sloan EP; Fenton GW; Standage KP
Biol Psychiatry; 1992 Mar; 31(6):600-6. PubMed ID: 1581439
[TBL] [Abstract][Full Text] [Related]
4. Human flash-VEP and quantitative EEG are independently affected by acute scopolamine.
Sannita WG; Balestra V; DiBon G; Marotta V; Rosadini G
Electroencephalogr Clin Neurophysiol; 1993 Apr; 86(4):275-82. PubMed ID: 7682931
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials.
Smith AT; Early F; Jones GH
Psychopharmacology (Berl); 1990; 102(4):535-43. PubMed ID: 2096411
[TBL] [Abstract][Full Text] [Related]
6. Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine.
Harding GF; Daniels R; Panchal S; Drasdo N; Anderson SJ
Doc Ophthalmol; 1994; 86(3):311-22. PubMed ID: 7813382
[TBL] [Abstract][Full Text] [Related]
7. [Visual evoked potentials in Alzheimer's and Parkinson disease].
Zimmer R; Walther H; Kurz A; Haupt M; Lehmann-Horn F; Lauter H
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1991 Dec; 22(4):239-45. PubMed ID: 1786786
[TBL] [Abstract][Full Text] [Related]
8. Visual evoked potentials in Alzheimer's disease: correlations with age and severity.
Philpot MP; Amin D; Levy R
Electroencephalogr Clin Neurophysiol; 1990; 77(5):323-9. PubMed ID: 1697523
[TBL] [Abstract][Full Text] [Related]
9. Specificity of visual evoked potentials alterations in Alzheimer's disease: comparison with normal aging, depression and scopolamine administration in young healthy volunteers.
Gilles C; De Buyl O; Génévrois C; Salama M; Mendlewicz J
Acta Neurol Belg; 1989; 89(3-4):226-7. PubMed ID: 2516969
[No Abstract] [Full Text] [Related]
10. The flash and pattern VEP as a diagnostic indicator of dementia.
Wright CE; Harding GF; Orwin A
Doc Ophthalmol; 1986 Jan; 62(1):89-96. PubMed ID: 3956362
[TBL] [Abstract][Full Text] [Related]
11. [Specificity of visual evoked potential alterations in Alzheimer's disease].
Gilles C; de Buyl O; Genevrois C; Salama M; Mendlewicz J
Neurophysiol Clin; 1991 Dec; 21(5-6):425-37. PubMed ID: 1808501
[TBL] [Abstract][Full Text] [Related]
12. Serial visual evoked potential recordings in geriatric psychiatry.
Sloan EP; Fenton GW
Electroencephalogr Clin Neurophysiol; 1992; 84(4):325-31. PubMed ID: 1378002
[TBL] [Abstract][Full Text] [Related]
13. Effects of scopolamine parenteral administration on the electroretinogram, visual evoked potentials, and quantitative electroencephalogram of healthy volunteers.
Sannita WG; Fioretto M; Maggi L; Rosadini G
Doc Ophthalmol; 1987 Dec; 67(4):379-88. PubMed ID: 3454320
[TBL] [Abstract][Full Text] [Related]
14. Visual evoked potentials in dementia: a meta-analysis and empirical study of Alzheimer's disease patients.
Pollock VE; Schneider LS; Chui HC; Henderson V; Zemansky M; Sloane RB
Biol Psychiatry; 1989 Apr; 25(8):1003-13. PubMed ID: 2720014
[TBL] [Abstract][Full Text] [Related]
15. Visual evoked potentials in elderly patients with primary or multi-infarct dementia.
Wright CE; Furlong PL
Br J Psychiatry; 1988 May; 152():679-82. PubMed ID: 3167445
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison.
O'Mahony D; Rowan M; Feely J; O'Neill D; Walsh JB; Coakley D
Gerontology; 1993; 39(4):228-40. PubMed ID: 8244051
[TBL] [Abstract][Full Text] [Related]
17. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
[TBL] [Abstract][Full Text] [Related]
18. Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude.
Potter DD; Pickles CD; Roberts RC; Rugg MD
Biol Psychol; 2000 Feb; 52(1):37-52. PubMed ID: 10686371
[TBL] [Abstract][Full Text] [Related]
19. Visual discrimination and P300 are affected in parallel by cholinergic agents in the behaving monkey.
Antal A; Kovanecz I; Bodis-Wollner I
Physiol Behav; 1994 Jul; 56(1):161-6. PubMed ID: 8084895
[TBL] [Abstract][Full Text] [Related]
20. Effects of single doses of diazepam, chlorpromazine, imipramine and trihexyphenidyl on visual-evoked potentials.
Bartel P; Blom M; van der Meyden C; de Klerk Sommers
Neuropsychobiology; 1988; 20(4):212-7. PubMed ID: 3255892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
